山东医药
山東醫藥
산동의약
SHANDONG MEDICAL JOURNAL
2001年
1期
6-8
,共3页
李宪章%宓现强%阮喜云%靳光娴%孙卓祥
李憲章%宓現彊%阮喜雲%靳光嫻%孫卓祥
리헌장%복현강%원희운%근광한%손탁상
蛛网膜下腔出血%组织型纤溶酶原激活物%纤溶酶原激活物抑制剂-1
蛛網膜下腔齣血%組織型纖溶酶原激活物%纖溶酶原激活物抑製劑-1
주망막하강출혈%조직형섬용매원격활물%섬용매원격활물억제제-1
对28例蛛网膜下腔出血(SAH)后患者的血浆组织型纤溶酶原激活物(t-PA)、纤溶酶原激活物抑制物(PAI-1)变化进行了观察,并与30例健康者进行对照。结果显示,与对照组比较,SAH后1~14天患者血浆纤溶活性明显增高;其中伴发脑血管痉挛(CVS)者出血第7天、14天血浆PAI-1活性均明显高于无CVS者;出血量多者血浆t-PA、PAI-1活性较高。提示血浆t-PA、PAI-1活性在SAH后呈动态变化,二者可能均参与SAH的发生、发展,其活性测定可望成为监测SAH、CVS及出血量的有效指标。
對28例蛛網膜下腔齣血(SAH)後患者的血漿組織型纖溶酶原激活物(t-PA)、纖溶酶原激活物抑製物(PAI-1)變化進行瞭觀察,併與30例健康者進行對照。結果顯示,與對照組比較,SAH後1~14天患者血漿纖溶活性明顯增高;其中伴髮腦血管痙攣(CVS)者齣血第7天、14天血漿PAI-1活性均明顯高于無CVS者;齣血量多者血漿t-PA、PAI-1活性較高。提示血漿t-PA、PAI-1活性在SAH後呈動態變化,二者可能均參與SAH的髮生、髮展,其活性測定可望成為鑑測SAH、CVS及齣血量的有效指標。
대28례주망막하강출혈(SAH)후환자적혈장조직형섬용매원격활물(t-PA)、섬용매원격활물억제물(PAI-1)변화진행료관찰,병여30례건강자진행대조。결과현시,여대조조비교,SAH후1~14천환자혈장섬용활성명현증고;기중반발뇌혈관경련(CVS)자출혈제7천、14천혈장PAI-1활성균명현고우무CVS자;출혈량다자혈장t-PA、PAI-1활성교고。제시혈장t-PA、PAI-1활성재SAH후정동태변화,이자가능균삼여SAH적발생、발전,기활성측정가망성위감측SAH、CVS급출혈량적유효지표。
The plasma tissue-type plasminogen activator(t-PA),plasminogenactivator inhibitor-1(PAI-1)in 28 patients with subarachnoid hemorrhage(SAH) were observed and compared with 30 healthy controls.Result showed that the fibrinolytic activity of patients with SAH on day 1~14 were significantly higher than that of normal controls.Plasma PAI-1 activity of patients with cerebral vascular spasma(CVS) were higher than those without CVS on day 7,14.The more was the amount of bleeding,the more were the levels of t-PA and PAI-1.It suggests that the activity of plasma t-PA and PAI-1 are dynamic changing.Both of them may involve in the development and prognosis of SAH.Determination of t-PA and PAI-1 are efficient items for early finding,diagnosis of CVS and amount of bleeding in patients with SAH.